MYRIAD
NEWS &
EVENTS		   Myriad
     
 
   

News Releases 





	

		Date
		Title (click to view the full text)
	

	

6-May-2008Myriad Genetics Reports Results for Third Quarter of Fiscal 2008




23-Apr-2008Myriad Genetics Announces Third Quarter Fiscal 2008 Financial Results Conference Call




6-Mar-2008Myriad Genetics to Present at the Lehman Brothers Healthcare Conference on March 19, 2008




6-Mar-2008Myriad Genetics to Present at Cowen Health Care Conference on March 18, 2008




5-Feb-2008Myriad Genetics Reports Results for Second Quarter of Fiscal 2008




29-Jan-2008Myriad Genetics Announces Completion of Phase 1 Trial of Anti-Thrombin Drug MPC-0920




23-Jan-2008Myriad Genetics, Inc. Expands Commercial and Clinical Infrastructure




22-Jan-2008Myriad Genetics Announces Second Quarter Fiscal 2008 Financial Results Conference Call




4-Dec-2007Myriad Genetics Submits IND on Vivecon




27-Nov-2007Myriad Genetics Elects Gerald P. Belle to Its Board of Directors




1-Nov-2007Myriad Genetics, Inc. Reports Results for First Quarter of Fiscal 2008




30-Oct-2007Myriad Genetics Sponsors Dance-Theater Event Hosted by Alzheimer's Association, New York City Chapter




22-Oct-2007Myriad Genetics Announces First Quarter Fiscal 2008 Financial Results Conference Call




10-Sep-2007Myriad Genetics Launches Awareness Advertising Campaign to Educate Women About Hereditary Risks of Breast and Ovarian Cancers




21-Aug-2007Myriad Genetics Reports Financial Results For Fiscal 2007




16-Aug-2007Myriad Genetics Initiates Phase 2 Clinical Trial of Azixa in Lung Cancer




8-Aug-2007Myriad Genetics Announces Fourth Quarter and Year-End Fiscal 2007 Financial Results Conference Call




26-Jul-2007Myriad Genetics Launches New Molecular Diagnostic Test




19-Jun-2007Myriad Genetics Collaborates With AstraZeneca on Phase 2 Trials




11-Jun-2007Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimer's Conference




15-May-2007$4 Trillion in Cost Savings to U.S. From New Disease-Modifying Alzheimer's Treatments




1-May-2007Myriad Genetics Reports Results for Third Quarter of Fiscal 2007




24-Apr-2007Myriad Genetics Announces Third Quarter Fiscal 2007 Financial Results Conference Call Tuesday, May 1, 2007 at 9:00 a.m. ET




18-Apr-2007Myriad Genetics Presents Tumor Origin Technology at AACR




17-Apr-2007Myriad Genetics Presents Azixa's Mode of Action at AACR




27-Mar-2007Myriad Genetics Initiates Phase 2 Clinical Trial of Azixa in Metastatic Brain Cancer




20-Mar-2007Myriad Genetics Completes Enrollment in Second Phase 3 Clinical Trial of Flurizan™ in Alzheimer's Disease




8-Mar-2007Myriad Genetics Initiates Phase 2 Clinical Trial of Azixa™ in Brain Cancer




5-Mar-2007Myriad Presents Additional Flurizan™ Phase 2 Study Data Demonstrating Benefit in Alzheimer's Patients




8-Feb-2007Myriad Genetics Announces Sale of Common Stock




7-Feb-2007Myriad Genetics Commences Public Offering of Common Stock




6-Feb-2007Myriad Genetics Reports Results for Second Quarter of Fiscal 2007




23-Jan-2007Myriad Genetics Announces Second Quarter Fiscal 2007 Financial Results Conference Call




8-Jan-2007Myriad Genetics Announces Results of Phase 2 Prostate Cancer Trial




2-Jan-2007Myriad Genetics to Present at the JPMorgan Healthcare Conference on January 8, 2007




7-Nov-2006Myriad Genetics, Inc. Reports Results for First Quarter of Fiscal 2007




24-Oct-2006Myriad Genetics Announces First Quarter Fiscal 2007 Financial Results Conference Call




24-Oct-2006Myriad Genetics Sponsors Clinical Trial in Pancreatic Cancer




22-Aug-2006Myriad Genetics Completes Enrollment in U.S. Phase 3 Clinical Trial of Flurizan for Alzheimer's Disease




22-Aug-2006Myriad Genetics Reports Financial Results for Fiscal 2006




8-Aug-2006Myriad Genetics Announces Fourth Quarter and Fiscal Year-end 2006 Financial Results Conference Call; Tuesday, August 22, 2006 at 10:00 a.m. ET




1-Aug-2006Myriad Introduces Enhanced BRACAnalysis® Test for Exceptionally High-Risk Breast Cancer Patients




19-Jul-2006Myriad's 24-Month Study of Flurizan Demonstrates Significant Benefit in Alzheimer's Disease Patients




2-May-2006Myriad Genetics Reports Results for Third Quarter of Fiscal 2006




2-May-2006Myriad Genetics Begins Phase 1 Trial of Anti-Thrombin Drug MPC-0920




18-Apr-2006Myriad Genetics Announces Third Quarter Fiscal 2006 Financial Results Conference Call; Tuesday, May 2, 2006 at 10:00 a.m. ET




11-Apr-2006Myriad and Abbott Enter Into Broad Discovery Collaboration




12-Mar-2006Myriad Genetics' Follow-on Study of Flurizan Demonstrates Continued Benefit in Alzheimer's Disease




8-Mar-2006Myriad Pharmaceuticals, Inc. Names Vice President of Marketing




7-Feb-2006Myriad Genetics Reports Results for Second Quarter of Fiscal 2006




31-Jan-2006Myriad Genetics Announces Second Quarter Fiscal 2006 Financial Results Conference Call; Tuesday, February 7, 2006 at 10:00 a.m. ET




22-Nov-2005Myriad Genetics and Abbott Extend Collaboration




15-Nov-2005Myriad Genetics' Follow-on Study of Flurizan Demonstrates Cognitive Improvement in Alzheimer's Disease




8-Nov-2005Myriad Genetics Announces Exercise of Over-Allotment Option by Underwriters of Public Offering




3-Nov-2005Myriad Genetics Announces Pricing of Common Stock Offering




28-Oct-2005Myriad Genetics Commences Offering of Common Stock




26-Oct-2005Myriad Genetics, Inc. Reports Results for First Quarter of Fiscal 2006




19-Oct-2005Myriad Genetics Announces First Quarter Fiscal 2005 Financial Results Conference Call; Wednesday, October 26, 2005 at 10:30 a.m. ET




18-Oct-2005Myriad Genetics Publishes Depression Gene Discovery




11-Oct-2005Myriad Genetics Advances Antithrombin Drug Development




29-Sep-2005Myriad Genetics Discovers COB1 Gene for Early-Onset Obesity




22-Sep-2005Myriad Genetics' Follow-on Study of Flurizan Demonstrates Continued Effect in Alzheimer's Disease




20-Sep-2005Myriad Genetics to Present at the UBS Global Life Sciences Conference on September 26, 2005




23-Aug-2005Myriad Genetics Reports Financial Results for Fiscal 2005




9-Aug-2005Myriad Genetics Announces Fourth Quarter and Year End Fiscal 2005 Financial Results Conference Call; Tuesday, August 23rd at 10:00 a.m. ET




2-Aug-2005Myriad Genetics Phase 3 Trial in Alzheimer's Disease is Proceeding on Schedule




29-Jun-2005Myriad Genetics is Exclusive Licensee of New Mayo Clinic Patent on Amyloid Lowering Drugs




20-Jun-2005Myriad Genetics Presents Results of Phase 2 Trial of Flurizan™ in Patients With Alzheimer's Disease




15-Jun-2005Myriad Genetics Announces Flurizan Phase 2 Results Presentation Conference Call




24-May-2005Myriad Genetics Licenses Cancer Drug Technology to Salmedix




4-May-2005Myriad Genetics Reports Results for Third Quarter of Fiscal 2005




2-May-2005Myriad Genetics Announces Third Quarter Fiscal 2005 Financial Results Conference Call




2-May-2005Myriad Genetics Reports Results of Phase 2 Trial of Flurizan™ in Patients With Alzheimer's Disease




18-Apr-2005Myriad Genetics Presents New Data on Cancer Drugs at AACR




13-Apr-2005Myriad Genetics Elects New Chairman John Henderson




7-Apr-2005Myriad Genetics Files Form S-3 Shelf Registration for Outstanding Shares of Common Stock




1-Mar-2005Myriad Initiates Phase 1 Trial of MPC-6827 in Metastatic Brain Cancer




8-Feb-2005Myriad Genetics Reports Results for Second Quarter of Fiscal 2005




1-Feb-2005Myriad Genetics' European Breast Cancer Patents Upheld by EPO




28-Jan-2005Myriad Genetics Announces Second Quarter Fiscal 2005 Financial Results Conference Call




20-Jan-2005Myriad Genetics to Present at the Piper Jaffray Healthcare Conference on January 25, 2005




12-Jan-2005Myriad Genetics Initiates Phase 3 Clinical Trial of Flurizan™ in Alzheimer's Disease




6-Jan-2005Myriad Genetics to Present at the 23rd Annual JPMorgan Healthcare Conference on January 12, 2005




28-Dec-2004Myriad Genetics Submits IND on Cancer Drug Candidate




9-Dec-2004Myriad Genetics Submits IND on MPC-6827 Cancer Drug




9-Nov-2004Myriad Genetics, Inc. Reports Results for First Quarter of Fiscal 2005




2-Nov-2004Myriad Genetics, Inc. Names Chief Operating Officer for Pharmaceuticals




26-Oct-2004Myriad Genetics Announces First Quarter Fiscal 2005 Financial Results Conference Call; Tuesday, November 9, 2004 at 10:00 a.m. ET




26-Oct-2004Myriad Genetics, Inc. Enhances Drug Discovery and Development Capability




20-Oct-2004Myriad Genetics, Inc. Expands Drug Development Infrastructure




18-Aug-2004Myriad Genetics Reports Financial Results for Fiscal 2004




11-Aug-2004Myriad Genetics Announces Fourth Quarter and Year End Results Conference Call; Wednesday, August 18, 2004 at 10:00 a.m. ET




20-Jul-2004Myriad Genetics Presents Phase I Results at International Conference on Alzheimer's Disease




8-Jul-2004Myriad Genetics Awarded $14.2 Million by NIH for Pathogen Drug and Diagnostic Development




10-Jun-2004Myriad Genetics to Present at Needham & Company's Third Annual Biotechnology Conference




4-Jun-2004Myriad Genetics Raises $50.2 Million




3-Jun-2004Myriad Genetics Commences Offering of 3,400,000 Shares of Common Stock




4-May-2004Myriad Genetics Reports Results for Third Quarter of Fiscal 2004




27-Apr-2004Myriad Genetics Announces Third Quarter Results Conference Call Tuesday, May 4, 2004 at 10:00 a.m. ET




20-Apr-2004Myriad Genetics Advances Drug Candidate for Chemotherapy-Induced Nausea




14-Apr-2004New Colon Cancer Gene Licensed Exclusively to Myriad Genetics




30-Mar-2004Myriad Genetics Elects John Henderson to Its Board of Directors




23-Mar-2004Myriad Genetics Elects Dennis Langer to Its Board of Directors




11-Mar-2004Myriad Genetics to Present Data on MPC-6827 at AACR




19-Feb-2004Myriad Genetics Improves Patient Access to Predictive Medicine




3-Feb-2004Myriad Genetics Reports Results for Second Quarter of Fiscal 2004




27-Jan-2004Myriad Genetics Announces Second Quarter Results Conference Call; Tuesday, February 3, 2004 at 10:00 a.m. ET




20-Jan-2004Myriad Genetics' Cancer Compound MPC-6827 Causes Tumor Regression in Pancreatic Cancers




13-Jan-2004Myriad Genetics' Cancer Drug Candidate MPI-176716 Causes Ovarian Tumor Remission




7-Jan-2004Myriad Genetics and Abbott Laboratories Expand Collaboration




4-Dec-2003Myriad Genetics Elects Robert Attiyeh to its Board of Directors




12-Nov-2003Myriad Genetics, Inc. Reports Results for First Quarter of Fiscal 2004




12-Nov-2003Myriad Genetics' Alzheimer's Drug Candidate Improves Learning




4-Nov-2003Q1 2004 Myriad Genetics Results Conference Call




26-Aug-2003Myriad Genetics Reports Financial Results for Fiscal 2003




19-Aug-2003Q4 2003 Myriad Genetics Earnings Conference Call




5-Aug-2003Myriad Genetics' Alzheimer's Disease Drug Candidate Cuts Production of Key Senile Plaque Initiator




10-Jul-2003Myriad Genetics and Mayo Clinic Form Collaboration to Develop Novel Alzheimers Drugs




25-Jun-2003Myriad Genetics Initiates Enrollment in Phase II Alzheimer's Drug Trial




6-May-2003Myriad Genetics, Inc. Reports Results for Third Quarter of Fiscal 2003




29-Apr-2003Myriad Genetics Announces Third Quarter Results Conference Call




4-Feb-2003Myriad Genetics, Inc. Reports Results for Second Quarter of Fiscal 2003




4-Feb-2003Myriad Genetics Discovers Major Depression Gene




28-Jan-2003Myriad Genetics Announces Second Quarter Results Conference Call, Tuesday, February 4, 2003 at 10:00 a.m. ET




22-Jan-2003Myriad Genetics, Inc. Names Jerry Lanchbury Senior Vice President of Research




21-Nov-2002Myriad Genetics Raises $57.3 Million




21-Nov-2002Myriad Genetics Names Richard Marsh As General Counsel




11-Nov-2002Myriad Genetics' CEO Peter Meldrum Named a Top 50 Scientific Visionary




5-Nov-2002Myriad Genetics, Inc. Reports Results for First Quarter of Fiscal 2003




29-Oct-2002Q1 2003 Myriad Genetics Earnings Conference Call




29-Oct-2002Myriad Genetics Discovers Major Cause of Hereditary Obesity




28-Oct-2002Myriad Genetics and Genetic Technologies Announce Strategic Licensing Agreement




12-Sep-2002Myriad Genetics Launches Direct to Consumer Advertising Campaign For Breast Cancer Test




22-Aug-2002Myriad Genetics Reports Financial Results for Fiscal 2002




22-Aug-2002Myriad Genetics Submits IND in Alzheimer's Disease to FDA




24-May-2002Myriad Genetics' BRACAnalysis Test Supported by Two New Studies; BRACAnalysis Essential in Saving Lives From Breast and Ovarian Cancer




16-May-2002Myriad Genetics Launches Fifth Predictive Medicine Product




7-May-2002Myriad Genetics, Inc. Reports Results for Third Quarter of Fiscal 2002




15-Apr-2002Myriad Genetics Publishes Major Obesity Gene Locus




3-Apr-2002Myriad Genetics and DuPont Form $24 Million Research Collaboration




15-Mar-2002Myriad Genetics Publishes Results of 10,000 Genetic Tests For Risk of Breast, Ovarian Cancer




12-Mar-2002Myriad Genetics and Abbott Laboratories Form Drug Discovery Collaboration




5-Feb-2002Myriad Genetics, Inc. Reports Results for Second Quarter of Fiscal 2002




29-Jan-2002Q2 2002 Myriad Genetics Earnings Conference Call Tuesday, February 5, 2002, at 10:00 a.m. ET




20-Dec-2001Myriad Genetics Submits Clinical Trial on Its Lead Prostate Cancer Drug, Flurizan™, to the FDA




4-Dec-2001Myriad Genetics and LabCorp Form Exclusive Predictive Medicine Marketing Alliance




27-Nov-2001Myriad Genetics and Biosearch Italia Form Drug Discovery Collaboration; Myriad to Screen Biosearch's Library of Natural Products




14-Nov-2001Myriad Genetics Launches Predictive Medicine Business in Brazil; - New MELARIS Melanoma Product Included




9-Nov-2001Myriad Genetics Files Shelf Registration




7-Nov-2001Myriad Genetics, Inc. Reports Results for First Quarter of Fiscal 2002




31-Oct-2001Myriad Genetics Announces First Quarter Results Conference Call, Wednesday, November 7, 2001, at 10:00 a.m. ET




30-Oct-2001Myriad Genetics and Pharmacia Form New Research Collaboration; - Myriad's Pharmacogenomics Technology Featured in the Collaboration -




25-Oct-2001Myriad Genetics Decodes Pufferfish Genome With International Consortium; Unique Vertebrate Genome to Aid Discovery of Drug Targets From Human Genome




9-Oct-2001Myriad Genetics Discovers Novel Anti-Cancer Drug




4-Oct-2001Myriad Genetics and University of Utah Publish Pioneering HIV Research in the Scientific Journal CELL




27-Sep-2001Myriad Genetics to launch Melaris™ - a predictive medicine test for melanoma




20-Sep-2001Myriad Genetics reports advanced pre-clinical progress with anti-HIV drug




6-Sep-2001Myriad Genetics Discovers Novel Hepatitis 'C' Target




21-Aug-2001Myriad Genetics Reports Fiscal 2001 Year-End Results




2-Aug-2001Myriad Pharmaceuticals Names Edward Swabb Senior Vice President And Head Of Development




18-Jul-2001Myriad Genetics Board Of Directors Approves Stockholder Rights Plan




27-Jun-2001Myriad Genetics Launches Predictive Medicine Testing In Germany, Switzerland And Austria




5-Jun-2001Myriad Genetics Discovers High Cholesterol Gene




23-May-2001Myriad Genetics Sponsors Ama Launch Of Hereditary Cancer Education Program




15-May-2001Myriad Genetics Awarded Three U.S. Patents And Eight International Patents




1-May-2001Myriad Genetics Drug Enters Preclinical Testing For Prevention Of Acute Thrombosis




1-May-2001Myriad Genetics Drug Enters Preclinical Testing For Prevention Of Acute Thrombosis




26-Apr-2001Myriad Genetics Reports Phase II Data On Lead Compound MPC-7869 At Recent Cancer Research Meeting




22-Feb-2001Myriad Elects New Chairman - Hugh D'andrade  -- Former Vice Chairman Of Schering-Plough




6-Feb-2001Myriad Genetics, Inc. Reports Results For Second Quarter Of Fiscal 2001




31-Jan-2001Myriad Genetics Publishes Prostate Cancer Gene




26-Jan-2001Myriad Genetics And Syngenta Complete Rice Genome Map




13-Dec-2000Myriad Genetics and Bayer Corporation Extend Proteomics Collaboration Through December 31, 2002




8-Dec-2000Myriad Genetics Acquires Exclusive Rights to Cancer Drug in Phase II Human Clinical Trials




29-Nov-2000Myriad Genetics Awarded Two Antibody Patents




14-Nov-2000Myriad Genetics Laboratories Awarded Contracts for Felon Identity Genomics




7-Nov-2000Myriad Genetics Discovers Novel Proteins in Heart Disease




2-Nov-2000Myriad Genetics, Inc. Reports Results for First Quarter of Fiscal 2001




31-Oct-2000Myriad Genetics Receives $41 Million in Equity Placement




19-Oct-2000Myriad Genetics Launches COLARIS™ in Canada




17-Oct-2000Myriad Genetics Introduces ProSpec -- New Generation Mass Spectrometry/Proteomics Technology




12-Oct-2000Myriad Genetics Awarded U.S. Patent on p16 Cancer Protein and Antibodies to Protein




4-Oct-2000Myriad Genetics Presents Prostate Cancer Gene at Annual ASHG Meeting




28-Sep-2000Myriad Genetics Launches COLARIS™ Colon Cancer Test




26-Sep-2000Myriad Genetics Discovers Novel Drug Target for Hepatitis B




5-Sep-2000Myriad Genetics Selected for Membership in Alliance for Cellular Signaling




29-Aug-2000Myriad Genetics Receives $22 Million in Equity Placement




22-Aug-2000Myriad Genetics Reports Fiscal 2000 Year-End Results




17-Aug-2000Myriad Genetics to Launch Colaris™ Colon Cancer Predictive Medicine Test




16-Aug-2000Myriad Genetics, Inc. Announces 2-for-1 Stock Split




10-Aug-2000Myriad Genetics, Inc. Names Sudhir Sahasrabudhe Executive Vice President of Research




20-Jul-2000Myriad Genetics, Inc. Names S. George Simon Vice President of Business Development




18-Jul-2000Myriad Genetics Awarded U.S. Patent for DNA Sequencing




12-Jul-2000Myriad Genetics and Harvard Pilgrim Health Care Agree to Offer Bracanalysis Testing




29-Jun-2000Myriad Genetics Gains $24 Million Equity Investment from European Pharmaceutical Company




13-Jun-2000Myriad Genetics' Education Video Wins Award from the American College of Obstetricians and Gynecologists




6-Jun-2000Myriad Genetics Discovers Novel Prostate Cancer Gene




31-May-2000Myriad Genetics Identifies Two Novel Proteins in Pharmacia Collaboration




23-May-2000Myriad Genetics Awarded US Patent on p10 Tumor Suppressor Gene




16-May-2000Myriad Genetics and Hitachi Establish Strategic Proteomics Alliance




9-May-2000Myriad Genetics, Inc. Reports Results for Third Quarter of Fiscal 2000




2-May-2000Myriad Genetics Awarded US Patent on Hypertension Gene




25-Apr-2000Myriad Genetics Reinforces Its Strong Intellectual Property Position With The Award Of Two More Patents In Breast Cancer




12-Apr-2000Myriad Genetics, INC. Withdraws follow-On Public Offering




9-Mar-2000Myriad Genetics Launches Molecular Diagnostic Testing In Canada




8-Mar-2000Myriad Genetics Launches Predictive Medicine Business in the United Kingdom and Ireland




17-Feb-2000Myriad Genetics Identifies Novel Drug Target for Colorectal Cancer




15-Feb-2000Myriad Genetics And Kaiser Permanente Sign Agreement For Breast Cancer Testing




10-Feb-2000Myriad Genetics, Inc. Reports Results For Second Quarter of Fiscal 2000




1-Feb-2000Myriad Genetics Launches Genetic Testing In Japan




26-Jan-2000Myriad Genetics Establishes Alliance With Biotecne for Familial Disease Genomics




20-Jan-2000Myriad Genetics And Searle Expand Pronet® Drug Discovery Alliance




5-Jan-2000Myriad Genetics And Roche Establish Pronet Alliance With $13 Million Potential




7-Dec-1999Myriad Genetics Awarded US Patent For P19 Tumor Suppressor Gene




18-Nov-1999Myriad Genetics Identifies New HIV Drug Target




11-Nov-1999Myriad Genetics, Inc. Reports Results for First Quarter of Fiscal 2000




26-Oct-1999Myriad Genetics Expands Pronet™ Collaboration with Schering AG




20-Oct-1999Aetna U.S. Healthcare® and Myriad Genetics Distribute American Medical Association Monograph to Educate Physicians on Genetic Testing




12-Oct-1999Bayer Corporation Options Two Additional Proteins from Myriad Genetics




30-Sep-1999Myriad Genetics Idenifies Six New Drug Targets




23-Sep-1999Myriad Genetics Discovers Diabetes Gene




15-Sep-1999Myriad Genetics Forms Strategic Alliance with Galileo Genomics




9-Sep-1999Myriad Genetics and Novartis Agricultural Discovery Institute Sign $33.5 Million Genomics Partnership




31-Aug-1999Myriad Genetics REPORTS FISCAL 1999 YEAR-END RESULTS




1-Jun-1999AMA Introduces New Physician Guide on Myriad Genetics Breast Cancer Test




13-May-1999Myriad Genetics Delivers Four Potential Drug Targets to Bayer




11-May-1999Myriad Genetics, Inc. Reports Results for Third Quarter




20-Apr-1999Myriad Genetics, Inc. Creates New Pharmaceuticals Subsidiary




18-Feb-1999Myriad Genetics is Awarded U.S. Patent for Gene Mutation Detection by Mass Spectrometry




9-Feb-1999Genetic Testing Revenue Up 131% Over the Same Quarter in Prior Year



		


  


Our lead candidate, Flurizan™, is currently in two Phase 3 clinical trials for Alzheimer's disease.


  





					
      
		

    

      
    

    

      
      

        

          
            
          
          
            © 2008 Myriad Genetics, Inc.